Physician profile
Seema Ahluwalia
NPI 1447231147
$15,974.14
in general payments reported to CMS, 2019-2025
70 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,023 · 2020: $1,423 · 2021: $2,067 · 2022: $2,446 · 2023: $2,090 · 2024: $3,287 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,605 · Consulting Fee: $375 · Education: $34.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,605.26 |
| Consulting Fee | $375.00 |
| Education | $34.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,430.09 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Novo Nordisk INC | $1,314.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $1,202.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals Lp | $935.56 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $886.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.32 | 2019-2025 | Jardiance |
| Medtronic, INC. | $688.26 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Mannkind Corporation | $655.32 | 2019-2025 | Afrezza |
| Dexcom, INC. | $550.40 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $536.59 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $493.59 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $460.66 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Amgen INC. | $443.31 | 2019-2025 | Evenity, Tepezza, Prolia |
| Amneal Pharmaceuticals LLC | $387.43 | 2019-2025 | Unithroid |
| Pfizer INC. | $375.00 | 2024 |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Ahluwalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.